soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Effects of on in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized Cardiovascular Outcomes Associated with Semaglutide
Pay in 4 interest-free payments of $6.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
























